Literature DB >> 2968281

Urodilatin (CDD/ANP-95-126) is not biologically inactivated by a peptidase from dog kidney cortex membranes in contrast to atrial natriuretic peptide/cardiodilatin (alpha-hANP/CDD-99-126).

M Gagelmann1, D Hock, W G Forssmann.   

Abstract

Atrial natriuretic peptide (CDD/ANP-99-126) is rapidly inactivated by a membrane preparations from dog kidney cortex. Inactivation occurs by cleavage of the ring structure in the position between Cys-105 and Phe-106. A unique proteolytic product separated by HPLC on reverse-phase column appears as a single peak which elutes prior the intact peptide. In contrast, CDD/ANP-95-126 (urodilatin) which is released from the kidney is not destroyed by proteolysis using an identical membrane preparation.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2968281     DOI: 10.1016/0014-5793(88)80436-8

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  15 in total

1.  B Type natriuretic peptide: a good omen in myocardial ischaemia?

Authors:  S P D'Souza; G F Baxter
Journal:  Heart       Date:  2003-07       Impact factor: 5.994

Review 2.  Atrial natriuretic peptide in cardiovascular biology and disease (NPPA).

Authors:  Wei Song; Hao Wang; Qingyu Wu
Journal:  Gene       Date:  2015-06-12       Impact factor: 3.688

Review 3.  The renal paracrine peptide system--possible urologic implications of urodilatin.

Authors:  M Meyer; C G Stief; A J Becker; M C Truss; A Taher; U Jonas; W G Forssmann
Journal:  World J Urol       Date:  1996       Impact factor: 4.226

4.  Hydrolysis of human and pig brain natriuretic peptides, urodilatin, C-type natriuretic peptide and some C-receptor ligands by endopeptidase-24.11.

Authors:  A J Kenny; A Bourne; J Ingram
Journal:  Biochem J       Date:  1993-04-01       Impact factor: 3.857

5.  Pharmacokinetics and pharmacodynamics of the vasopeptidase inhibitor, omapatrilat in healthy subjects.

Authors:  Wei-Chi Liao; Ole Vesterqvist; Carol Delaney; Mohammed Jemal; Irene Ferreira; Neville Ford; Brian Swanson; Howard Uderman
Journal:  Br J Clin Pharmacol       Date:  2003-10       Impact factor: 4.335

6.  Nonlinear mixed effect modeling of the pharmacodynamics of natriuretic peptides in rats.

Authors:  Y Hashimoto; S Mori; N Hama; K Nakao; H Imura; M Yamaguchi; M Yasuhara; R Hori
Journal:  J Pharmacokinet Biopharm       Date:  1993-06

7.  Urodilatin: a new peptide with beneficial effects in the postoperative therapy of cardiac transplant recipients.

Authors:  M Hummel; M Kuhn; A Bub; H Bittner; D Kleefeld; P Marxen; B Schneider; R Hetzer; W G Forssmann
Journal:  Clin Investig       Date:  1992-08

8.  Hydrolysis of iodine labelled urodilatin and ANP by recombinant neutral endopeptidase EC. 3.4.24.11.

Authors:  Z A Abassi; E Golomb; R Agbaria; P P Roller; J Tate; H R Keiser
Journal:  Br J Pharmacol       Date:  1994-09       Impact factor: 8.739

9.  Clearance mechanisms of atrial and brain natriuretic peptides in rats.

Authors:  Y Hashimoto; K Nakao; N Hama; H Imura; S Mori; M Yamaguchi; M Yasuhara; R Hori
Journal:  Pharm Res       Date:  1994-01       Impact factor: 4.200

10.  Bronchodilator and pre-protective effects of urodilatin in bovine bronchi in vitro: comparison with atrial natriuretic peptide.

Authors:  J E Nally; C C Docherty; R A Clayton; N C Thomson
Journal:  Br J Pharmacol       Date:  1995-04       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.